This discussion integrates clinical findings with current literature to emphasize the importance of recognizing and managing rare adverse reactions associated with novel biologic therapies like risankizumab. Given the growing use of IL-23 inhibitors in treating autoimmune diseases, further research is needed to fully understand their safety profile, including their potential hematologic adverse effects like thrombocytopenia. Here, IL37 is linked to autoimmune disease.